From their the Q2 report, despite affected by Covid to have higher operating cost, they still seem to maintain a good cash flow. I believe the time will come very soon
this is a solid company. look at the PE, market cap and sector it covers, market exposure. despite all the market ups and downs these 2 weeks, it didn't drop much
The Group’s 1HFY20 performance was hit by a one-off impairment of RM50m on unsold property inventories as well as Covid19-related disruptions, which resulted in a net loss of RM15.8m (compared with a net profit of RM67.0m in 1HFY19). Going forward, consensus is forecasting the Group to post net profits of RM95m in FY20 and RM145m in FY21, which translates to forward PERs of 17x and 11x, respectively.
United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19
TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided abUnited Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19out the trial.
The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.
The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.
The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”
The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.
Sarawak minster says that the delay of pan Borneo highway is too far behind of schedule and therefore eed to appoint consultant as JKR not able to cope with the massive project. I was wondering isn't Edgenta consultant arm, Opus sign a MOU with Sarawak's JKR. I wonder wat is that for
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
daichafan
10 posts
Posted by daichafan > 2020-09-10 21:11 | Report Abuse
From their the Q2 report, despite affected by Covid to have higher operating cost, they still seem to maintain a good cash flow. I believe the time will come very soon